2023 ISPE Facilities of the Future Conference

The 2023 ISPE Facilities of the Future Conference will explore advancements in pharmaceutical technology and what pharmaceutical manufacturing facilities will look like in the future. Featuring technical and inspirational presentations and case-studies from industry leaders already planning and building “facilities of the future”.

This conference will look at new manufacturing advances, the challenges, innovative technologies, and regulatory factors impacting the adeptness of today’s pharmaceutical companies to stay competitive and cost-effective. Speed to patient is repeatedly a key requirement in project delivery and COVID-19 accelerated many trends and collaborations. Considering the lessons learnt from the pandemic, transformations and updates in facility design and project execution approaches, as necessary elements, will be presented.

During the conference, we will look at the maturation of the biopharmaceutical industry. Regulatory agencies have matured along with the biopharmaceutical industry, and we expect programs for cell and gene therapies to advance in the next few years. Emphasis will be on bio manufacturing with process control and automation, workforce of the future with the right expertise, and scaling-up.

Both new and legacy pharmaceutical facilities will be featured in our conference, with a focus on efficiency and cGMP compliancy, while adopting emerging technologies to improve drug quality. The impact of disruptive technologies and Pharma 4.0, highly automated processes using the Internet of Things (IoT), Artificial Intelligence (AI), robotics, advanced analytics, the use of digital twins, and machine learning will be covered. Additionally, facility designs that embrace the attributes of facilities of the future such as adaptability and flexibility will be included, with a particular emphasis on single-use, regenerative medicines, and drug product facilities.


What Can You Expect?

Watch some of the 2022 ISPE Facilities of the Future Conference highlights to get a taste of how you'll benefit from compelling discussions and knowledge exchange opportunities on the latest advancements in pharmaceutical manufacturing facilities.


Conference Content Areas 

This conference brings together diverse experts to share best practices and benchmark solutions for new and existing facilities. ISPE will be the leader to set the pace for knowledge sharing that speaks to the current and future needs of the industry. 

The 2023 Facilities of the Future Conference Programme Committee is requesting proposals aligning with the following content areas:

  • Bio Manufacturing

    The maturation of the biopharmaceutical industry will be explored. We expect programs for cell and gene therapies to advance in the next few years. Emphasis will be on bio manufacturing with process control and automation, workforce of the future with the right expertise, and scaling-up.

  • Chemical Synthesis

    There has been a significant re focus on small molecule facility design and technologies in recent years with the increasing demand for a range of chemically synthesised products including peptides and oligonucleotides. The industry is seeing a wider adoption of continuous process flow chemistry, solid state synthesis, and advanced catalysis which is initiating changes to facility designs such as those relating to containment, flexibility and cleanliness. Sessions will focus on the new processes, facility designs and technologies.

  • Digital Transformation and Pharma 4.0

    The Digital Transformation Journey is one of the most important strategic challenges in today’s pharma organizations. The digital transformation is a holistic approach. This focus area will address the key challenges of the transformation which are: Integration, cultural change, data availability, and strategic ownership based on practical case studies.

  • Innovative Project Delivery

    This conference will look at new manufacturing advances, the challenges, innovative technologies, and regulatory factors impacting the adeptness of today’s pharmaceutical companies to stay competitive and cost-effective. Speed to patient is repeatedly a key requirement in project delivery and COVID-19 accelerated many trends and collaborations. We are interested in sessions considering the lessons learnt from the pandemic, transformations and updates in facility design and project execution approaches, as necessary elements.

  • Manufacturing Trends

    Applying harmonized approaches to innovative design solutions and project delivery strategies to ensure that quality therapeutic products are brought to market in an efficient manner to improve patient health will be the focus of this content area. Sessions with focus on these elements should be submitted.

  • Sustainability

    Sustainability with respect to governance in the pharmaceutical industry should focus on product quality, and transparency. Sessions with the focus on how companies are adopting ethical standards combined with patient focus, while leveraging digital technology should be submitted.


Program Committee

Chair
Jeffrey A. Biskup, PE
CEO and Chairman of the Board
CRB
Past Chair
James A. Breen, Jr., PE
Vice President, Lead Biologics Expansion
Janssen Pharmaceuticals
Mark A. Butler
President and Managing Director
IPS
Lindsey E. Daniel, PE
Product Operations Program Manager
Takeda
Placeholder Person Graphic
Dedric Allan Day
Director- Process Engineering Technical Center
Eli Lilly and Co
Lou W. Kennedy
CEO and Owner
Nephron Pharmaceuticals
Board Liaison
Austin G. Lock
Technical Director, Group Head of Technology
PM Group
Dina Manfredi
Director of Sales and Business Development
GMP Systems Inc
Carolina Isabel Serrano Martinez
Operations Improvement Engineer
Eli Lilly & Co
Brian K. Vaughn
Chair, North America/South America Affiliate Council
CRB